Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

By T. Kuehn, I. Bauerfeind, T. Fehm, B. Fleige, M. Hausschild, G. Helms, A. Lebeau, C. Liedtke, G. von Minckwitz, V. Nekljudova and 4 more. The Lancet Oncology, 2013

1,269 citations recorded by the source corpus.

Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/a05907a7c78680e4e292143448fbad50935ee715

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Goldhirsch
2. A. Coates
3. R. Gelber
4. B. Thürlimann
5. H. Senn
6. E. Rutgers
7. M. Piccart-Gebhart
8. M. Gnant

Citations in the corpus

• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, result): “The recently published SENTINA and ACOSOG Z1071 studies demonstrated lower detection rates and higher rates of false-negatives when SLNB is carried out after systemic therapy, compared with SNLB that is carried out before neoadjuvant chemotherapy [14, 15].”
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, background): “Sentinel node biopsy is feasible and accurate after neoadjuvant chemotherapyand allows precise assessment of pCR [92 – 95].”